On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Tandem Diabetes Care shares ticked up after hours today on third-quarter results that topped the consensus forecast.

Insulet’s PODD robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on the significant growth opportunities in the Type 2 diabetes space. PODD ...

Recent recalls of insulin pumps may hinder growth in Medtronic's diabetes business, despite partnerships with Abbott. I recommend selling Medtronic stock until it achieves significant innovation ...

Insulet is the first and only company to offer a tubeless automated insulin delivery (AID) system with full control from a ...

Type 1 Diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic beta cells, leading to ...

In people with T1D, use of continuous subcutaneous insulin infusion (CSII) and CGM sensors is likely to expand with the use of closed loop technology (semi-automated linked CGM and CSII). This is ...